Potential drug-drug interactions among pneumonia patients: do these matter in clinical perspectives?

Table 2 Prevalence and levels of potential drug-drug interactions

PDDIs	Patients: n (%)
Prevalence of pDDIs^a
Overall prevalence of pDDIs	315 (73.1)
Number of pDDIs per patient
1–2	141 (32.7)
3–4	76 (17.6)
>4	98 (22.7)
Severity-wise prevalence of pDDIs
Contraindicated	47 (10.9)
Major	232 (53.8)
Moderate	222 (51.5)
Minor	74 (17.1)
Levels of pDDIs^b
Severity-levels
Contraindicated	50 (3.8)
Major	572 (43.4)
Moderate	606 (46)
Minor	90 (6.8)
Documentation-levels
Excellent	137 (10.4)
Good	491 (37.2)
Fair	690 (52.3)

PDDIs Potential drug-drug interactions
^aPercentage was calculated out of total number of patients i.e., 431
^bPercentage was calculated out of total number of potential drug-drug interactions i.e., 1318
Overall-prevalence is the occurrence of at least one pDDI irrespective of severity type. Total number of pneumonia patients were 431. Therefore, overall-prevalence of pDDIs was 73.1% (315 out of 431)

ISSN: 2050-6511